Respiratory syncytial virus (RSV) causes significant mortality in hospitalized adults.
| INTRODUCTION
There is increasing evidence that respiratory syncytial virus (RSV) is a common cause of respiratory tract infections (RTI) in adult patients, 1 often with a complicated course of disease. [2] [3] [4] [5] Among hospitalized elderly ≥65 years of age mortality is as high as 8%, 2 but among high-risk groups as patients with chronic heart or lung disease, long-term care facility residents and immunocompromised patients as lung or hematopoietic cell transplant (HCT) recipients, RSV may even lead to mortality rates over 50%. 2, 3, 6, 7 ---------------------------------------------------------------------------------------------------------------------------This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
With the widespread implementation of rapid tests for respiratory viruses in-hospital care settings, early detection of RSV enables early treatment with either aerosolized or oral ribavirin 6, [8] [9] [10] [11] [12] [13] [14] and future medicaments as fusion protein inhibitors (eg, presatovir), nucleoside inhibitors (eg, lumicitabine), 15 and viral replication lowering immunoglobulins (eg, palivizumab), which might have an additional positive effect to ribavirin. 11, [16] [17] [18] Ideally, in light of effectivity and potential side effects, treatment should be targeted to patients at the highest risk of a lifethreatening infection. Identification of RSV-infected patients at high-risk of death is therefore necessary to improve targeted therapy and clinical outcomes. In addition, the prediction of individual prognosis improves decision making on the necessity to apply supportive in-hospital management as intensive care unit (ICU) admission and strict isolation procedures. 3 However, a validated prognostic model to identify adult patients with a high mortality risk is not available. Therefore, we aimed to establish factors associated with poor prognosis and externally validate and update existing models to predict mortality in hospitalized RSV-infected adults.
| METHODS

| Study population
We performed a single center cohort study to validate prognostic models for poor outcomes in hospitalized adults with RSV. In the validation cohort we included adult patients (≥18 years) with a laboratory confirmed community acquired RSV-infection between January 2005 and April 2018 who were admitted to the University Medical Center Utrecht (UMCU), a 1042-bedded tertiary care hospital in the central region of The Netherlands. We excluded patients with hospital acquired RSV-infection (RSV result >48 hours after admission). When patients had more than one hospitalized RSVinfection episode during the study period, only the first episode was included. RSV positive patients were identified retrospectively using the microbiology laboratory database of the UMCU. During the inclusion period, in-house reverse transcription polymerase chain reaction (RT-PCR) was used for detection of RSV and other respiratory viral pathogens 19, 20 in respiratory tract specimens. A positive RSV result was defined as having a cycle time (Ct) value les than 40. 21 For immunocompromised patients, the conventional inhouse RT-PCR was replaced by a qualitative RT-PCR-the FilmArray respiratory viral panel version 1.7 (BioFire Diagnostics, Salt Lake City) 22 from November 2016 onwards. Collection of predictor and outcome variables was performed retrospectively from the electronic patient files. This study was assessed by the medical ethics committee of the UMCU (METC protocol no 18-410/C). Due to the retrospective nature of the study, informed consent was not required. Results were reported to conform with the transparent reporting of a multivariable prediction model for individual prognosis or Diagnosis (TRIPOD) statement (Table S1 ). 23 
| External validation
We searched available literature on predictive models for RSV prognosis in the MEDLINE. We aimed to validate models predicting mortality, but also included studies using a composite outcome including mortality. For the external validation, we applied the included original prognostic models to our study cohort exactly as they were published, with similar definitions of predictor variables and outcomes (Table S2 ). [24] [25] [26] [27] If the intercept from the original model was not reported, we calculated a new intercept by recalibration. We compared the discriminative ability of the models using the Harrell's C-statistic. Calibration of the models was assessed in calibration plots. [28] [29] [30] 
| Model update
We selected the model with the best discrimination and calibration for further updating. 24 In view of increasingly shorter turnaround times of molecular diagnostics and increased effectiveness of antiviral treatment when given at an early stage, 6 we first removed any eventual predictors that could not be assessed at the time of presentation/RSV diagnosis, eg, bacterial coinfection. Furthermore, we replaced binary predictors with continuous to avoid loss of information, eg, temperature instead of fever. Next, we recalibrated the calibration slope and intercept by refitting this adapted model in the validation cohort. Consequently, we tested the incremental value of the model by adding objectively assessable predefined predictor variables (age, gender, urea, confusion, cardiovascular comorbidities, immunocompromised status, and the number of other comorbidities), based on the existing prognostic models for poor outcomes in patients with positive influenza virus. 26, 27, 31 We performed backward variable selection based on the Akaike information criterion and Occam's razor principle. Finally, we performed internal validation with optimism correction by bootstrap. 32 Discrimination and calibration of this final updated and extended model was assessed for inhospital mortality, 30-day mortality and a composite outcome consisting of in-hospital death, ICU-admission and/or need for mechanical ventilation separately. Furthermore, we performed a decision curve analysis to provide insight into the range of predicted risks for which the final model results in better clinical decision making, eg, is better than either classifying all or none of the patients as having the outcome. 33 
| Statistical analysis
For the validation cohort, we accounted for missing values of predictors using a multiple imputation model including baseline characteristics, predictors, and outcome variables. Results shown are pooled from the 10 multiple imputed datasets. 34 Calibration plots were derived from all 10 multiple imputed datasets combined.
Analyses were performed by the SPSS version 25 (IBM Corp) and the rms, mice, survival, and rmda packages of R-3.1 for Windows (http://cran.r-project.org).
| RESULTS
| Validation cohort
We included 192 hospitalized, RSV-infected adult patients.
Demographics and characteristics of the included patients are displayed in Table 1 were admitted to the ICU within the first 48 hours of admission.
The median length of hospital stay was 5 days (IQR, 3-10) and 77 patients (40.1%) had a hospital stay ≥7 days. In total, 147 patients (76.6%) were treated with antibiotics empirically and 25 patients (13.0%) were treated with oral ribavirin, of whom 18 for ≥7 days. Over the years, the annual number of included patients increased, with no clear changes in in-hospital mortality rate ( Figure S1 ).
| External validation
We found five studies that developed a prognostic model for hospitalized RSV-infected adult patients, of which two to predict mortality 24, 25 and three to predict disease progression to a lower RTI [34] [35] [36] [37] ( Figure S2 ). The two models to predict mortality were included for external validation. A detailed overview of these two The calibration plot of this model plotting predicted against observed survival at 30 days, showed reasonable calibration ( Figure 2B ).
| Model update
We updated and extended the model of Park et al, 24 No further definition or details given.
or need for mechanical ventilation. The updated model showed good calibration for the composite outcome ( Figure 3) . Results of the decision curve analysis of the updated model is shown in Figure 4 . For the whole range of predicted risks, the updated prognostic model showed a positive net benefit. However, only with a risk threshold-eg, a predicted risk threshold that can be used for decision-making regarding therapy-above 40%, the updated model improved the net benefit as compared to the original model of Park et al. 24 
| DISCUSSION
We showed that hospitalized, RSV-infected adults had an 8% inhospital and 8% 30-day mortality rate. We validated and updated models to predict poor outcome in these patients at the time of RSV diagnosis. This model can be used to develop a risk score or decision tool to guide decisions on treatment with ribavirin, immune globulins, and other antivirals and on site-of-care and strict isolation procedure decisions, as is already common practice for influenza virus. 38 These interventions might improve clinical outcomes for patients with lifethreatening disease.
To our knowledge, this is one of the largest studies in RSVinfected adult patients in a hospital care setting. We found a high percentage of 8% in-hospital mortality, which is in line with 8% to 9% mortality rates reported in former publications. 2, 6, 24, 25 This high mortality rate underlines the great importance of targeted treatment for these patients. Also, this is the first study to externally validate existing models to predict poor prognosis in RSV-infected hospitalized adult patients, and allows for a head-to-head comparison of two published models. Unfortunately, model performance in the development cohorts was not described, 30 but the poor to moderate discriminative abilities of both models in our validation cohort with C-statistics under 0.7 with CI close to or overlapping 0.5, indicate that both models are not suitable for use in daily practice, at least not 30 Geographical validation is also very likely to have played a role and affected the performance of these models in our validation cohort, 30 since both development studies were performed in Asia. Temporal and domain validationwith 37% 24 and 14% 25 vs 65% immunocompromised patients for example-might also have resulted in lower prediction accuracy of the two models, although the proportions of our patients who met the outcomes were quite similar to the development studies. 30 Another, maybe the most important factor that might have caused the moderate performance of both models at external validation, was the relatively small cohort in which these models were developed, with a rather low number of events causing overfitted estimations of predictor effects. 32 If internal validation methods as bootstrap would have been performed after development of these models, poor external validation might have been foreseen. 32, 39 During the model update, the viral load (eg, Ct value) of RSV was not considered a useful predictor. First, the interpretation of single viral load measurements is difficult. Not only are viral loads of respiratory viruses highly dependent on variation in sampling timing, location and technique, they also rise and drop rapidly and it is known that symptoms mostly follow the highest peak in viral load. 40, 41 Second, since more and more rapid qualitative molecular methods are implemented, viral loads will not always be available. In addition to the fact that we had a large cohort and performed external validation according to current guidelines, we performed a model update according to the TRIPOD statement, 23 including internal validation procedures. 30 However, some limitations of our study need to be addressed. First, we had a limited amount of patients with the primary outcome. For studies validating prognostic models, there is no solid sample size recommendation, but it is recommended to consider at least the number of predictors, the total sample size and the event fraction. [42] [43] [44] The low number of events in our study might have . The horizontal gray line is the net benefit when all RSVinfected hospitalized adults are considered as not having the poor outcome; vertical gray line is the net benefit when all RSV-infected hospitalized adults are considered as having the poor outcome. The higher the net benefit (blue line) at any given threshold, the better the model performs. Example: with a risk threshold of 25% (threshold above which we would treat), the net benefit (derived from the true positives and true negatives) is 5.33 per 100 patients when using the original model of Park et al 24 and 5.95 when using the updated model. RSV, respiratory syncytial virus; ICU, intensive care unit
